Latest Conference Coverage

In a late-stage trial, telitacicept demonstrated significant and rapid clinical improvements in gMG, achieving notable symptom reductions, improved quality of life, and strong safety outcomes.

The chief medical officer at Cognito Therapeutics provided a clinical overview on promising findings surrounding the company’s gamma sensory stimulation device in patients with Alzheimer disease. [WATCH TIME: 10 minutes]

High doses of RNS60 led to greater number of patients with modified Rankin scale scores between 0-2, improved EQ-5D-5L index score, and enhanced NIHSS score at each pre-specified time point over placebo.

The vice president of research at Cognition Therapeutics provided commentary on the safety of investigational CT1812 and its role in immune response and synapse-related pathways. [WATCH TIME: 3 minutes]

Elizabeth Head, PhD, a professor in the Department of Pathology and Laboratory Medicine at the University of California, Irvine, shed light on the emerging research and trials surrounding the interplay between Alzheimer disease and Down syndrome.

In late-breaking findings from the TRANQUIL study presented at AAN 2025, the wearable demonstrated significant improvements in tremor reduction and daily functioning over a sham device.

The senior director of mission programs at The ALS Association discussed how the thinkALS Toolkit can aid general neurologists in identifying and referring suspected cases more efficiently. [WATCH TIME: 5 minutes]

Patients treated with efgartigimod for myasthenia gravis were found to have a higher incidence and severity of infections compared to those treated with immunoglobulins.

The physician assistant at UCSF Movement Disorder and Neuromodulation Center reflected on the value of AMDAPP in fostering professional connection, education, and patient-centered care among movement disorder APPs. [WATCH TIME: 3 minutes]

Experts discussed recent advancements in diagnostic criteria, imaging techniques, and the evolving understanding of multiple sclerosis subtypes and treatment responses. [WATCH TIME: 10 minutes]

Emer MacSweeney, MD, a consultant neuroradiologist and trial investigator of the phase 3 APOLLOE4 study, provided a clinical view of the latest study findings, and the difficulties with finding treatments for APOEε4/4 carriers of Alzheimer disease.

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed the current research landscape, clinical challenges, and future directions for noninvasive neuromodulation techniques in neurorehabilitation. [WATCH TIME: 4 minutes]

The neuroradiologist at Mayo Clinic provided clinical insights on the controversy with two recently published Alzheimer criteria, with one diagnosing the disease based on biomarkers alone vs clinical symptoms. [WATCH TIME: 4 minutes]

Cassandra Gorsuch, PhD, chief scientific officer at Precision Biosciences, discussed the company’s ARCUS gene editing platform, its innovative approach to treating Duchenne muscular dystrophy, and promising preclinical data presented at MDA 2025.

The professor of neurology at the University of Texas Health Science Center San Antonio discussed some of the challenges with therapeutic development for OPMD, as well as advances and barriers to gene therapy approaches. [WATCH TIME: 4 minutes]

The clinical associate professor of neurology and neurosurgery at NYU Langone Health emphasized the importance of rapid, targeted blood pressure reduction and bundled care to improve outcomes in patients with intracerebral hemorrhage. [WATCH TIME: 4 minutes]

Relative to previously approved therapies like rimegepant, ubrogepant, and zavegepant, AXS-07 resulted in better 2-hour pain relief, sustained pain relief, and reduced use of rescue medications.

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania discussed evolving insights into the cellular immunology of multiple sclerosis. [WATCH TIME: 4 minutes]

Harmony Biosciences’ phase 3 study will assess EPX-100, a repurposed antihistamine, as a potential treatment for Lennox-Gastaut syndrome, targeting seizure reduction and improved outcomes.

The clinical professor of stroke neurology at Stanford University discussed the clinical rationale and evidence supporting early, intensive blood pressure lowering in patients with intracerebral hemorrhage.

Murali Doraiswamy, MD, MBBS, a professor of psychiatry and geriatrics at Duke University School of Medicine, gave clinical follow-up on a pivotal analysis of the phase 3 APOLLOE4 study testing a novel therapeutic for Alzheimer disease.

Newly presented open-label extension results at AAN 2025 suggest that investigational ZYN002, a cannabidiol gel, may help improve irritability in children and adolescents living with Fragile X syndrome.

The staff scientist at Gladstone Institutes talked about leveraging AI-driven behavioral analysis to better model and assess Alzheimer disease progression in preclinical studies. [WATCH TIME: 2 minutes]

Findings from a phase 3 study revealed that patients with Parkinson disease switching to IPX203 had greater benefits in good ON time when also taking lower doses of dopamine agonists.

The professor of neuroscience at the Imperial College London discussed the emerging role of GLP-1 analogs as neuroprotective agents with potential benefits in neurodegenerative conditions. [WATCH TIME: 4 minutes]

The director of the UCLA Goldberg Migraine Program discussed the advantages, evidence base, and evolving payor support for CGRP-targeting therapies as potentially a first-line option in migraine prevention. [WATCH TIME: 5 minutes]

The clinical professor of stroke neurology and neurocritical care at Stanford University advocated for early and intensive blood pressure reduction in patients with intracerebral hemorrhage to limit hematoma expansion and improve outcomes. [WATCH TIME: 5 minutes]

The ENABLE phase 4 study will evaluate the real-world safety, efficacy, and patient experience of ublituximab in relapsing multiple sclerosis over a 96-week period.